The global glaucoma treatment market holds a valuation of USD 5.7 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.18%, and is expected to hold a market value of around USD 8.0 Billion in 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 5.7 Billion |
| Market Value 2023 | USD 5.8 Billion |
| Market Value 2033 | USD 8.0 Billion |
| CAGR 2023 to 2033 | 3.2% |
| Market Share of Top 5 Countries (2022) | 55.2% |
| Key Market Players | AERIE Pharmaceuticals, Inc.; Cipla Inc.; Akorn Operating Company LLC; AbbVie; Bausch & Lomb Incorporated; Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd. |
Glaucoma is the most common and second leading eye diseases and causes irreversible blindness by damaging optic nerve by high eye pressure. The common glaucoma type is open angle glaucoma causes vision loss with no apparent symptoms, while angle closure glaucoma is infrequent glaucoma and occurs with symptoms like eye pain with visual disturbance, and nausea. Glaucoma aetiology includes age-related macular degeneration, cataract, diabetic retinopathy, glaucoma, uncorrected refractive errors, and other factors.
According to the World Health Organization (WHO), about 4.5 million people suffers from glaucoma globally in 2019. As per published data of National Glaucoma Research data in 2022, currently glaucoma patients are more than 80 million and it is anticipated to increase beyond 111 million till 2040.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The glaucoma treatment industry expanded at a CAGR of 3.0% for 2017 to 2022 period due to increasing prevalence of glaucoma disease and diabetes, old - age population, and innovative technologies with novel pharmacological discoveries.
The global glaucoma treatment market contributes 15.9% value share to the global eye disorders and treatment market valued at USD 35.8 Billion in 2022.
The glaucoma condition is frequently known as silent thief of sigh since most of the glaucoma variations rarely show pain or other obvious signs before causing noticeable vision loss; hence, number of glaucoma cases are rising. Government and pharmaceutical company activities are raising awareness of glaucoma are promoting the expansion of the market for glaucoma treatments.
Another factor driving the expansion of the market of glaucoma treatment is technological development in eye drops, which are the primary glaucoma control measure. Pharmaceutical and biotech businesses are also investing in the creation of novel glaucoma products. The most common medications used to treat glaucoma today include alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogues, and combinations of these drugs. In contrast, the absence of discomfort and symptoms other than apparent vision loss are regarded as a problem for the market of glaucoma treatment.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 2.44% |
| Jul-Dec (H2), 2021 (A) | 3.55% |
| Jan-Jun (H1),2022 Projected (P) | 2.33% |
| Jan-Jun (H1),2022 Outlook (O) | 2.57% |
| Jul-Dec (H2), 2022 Outlook (O) | 3.39% |
| Jul-Dec (H2), 2022 Projected (P) | 3.19% |
| Jan-Jun (H1), 2023 Projected (P) | 2.70% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 24 ↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 13 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 20 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | (-) 17 ↓ |
Principal Consultant
Rising elderly populations and glaucoma awareness in several countries, as well as an increase in government and private sector initiatives to cure glaucoma and reduce the financial treatment cost, are expected to drive the glaucoma market demand.
An increase in the number of new innovative products and clinical trial products is boosting the industry's growth. The University of Minnesota College of Pharmacy's Department of Medicinal Chemistry and the Institute for Therapeutics Discovery & Development (ITDD) collaborated to create a novel medicine for the treatment of glaucoma in 2022.
The market is primarily driven by the ophthalmology industry's rapid technical advancements and the growing use of innovative surgical methods. The need for optometrists has grown as a result of advancements in optical coherence tomography (OCT), selective laser trabeculoplasty (SLT), medical imaging, progression analysis software, and microinvasive glaucoma surgery (MIGS). This is one of the key driving forces for the market's expansion. The size of the glaucoma market is anticipated to increase with the introduction of laser therapy and pharmaceuticals for the condition.
It is challenging to treat glaucoma because it does not initially cause symptoms like pain or vision loss. Glaucoma surgery also frequently results in a number of post-operative problems. Shortage of experienced healthcare workers and a lack of knowledge about glaucoma treatment in emerging nations may impede the growth of the industry of glaucoma treatment in the years to come.
The glaucoma drug approval process is stringent, and sometimes need to remove or reject a product from market due to safety issues concerns and also, by various other reasons, including bioavailability, drug performance, efficacy, PH properties, toxicity. Apotex Corp, for example, is recalling 22,027 bottles of timolol maleate ophthalmic solution in 2023 due to drug samples failed to meet stability specifications.
Drug side effects are also associated with glaucoma treatment. Prostaglandin analogues, for example, have side effects such as eye redness and itching; beta blockers have side effects such as low blood pressure and decreased libido; and Rho kinase inhibitors have side effects such as stinging and small bleeds on the white part of the eye.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 29.7% |
| Market Share (2033) | 29.8% |
| BPS Analysis | 9 |
| Country | China |
|---|---|
| Market Share (2023) | 11.1% |
| Market Share (2033) | 11.3% |
| BPS Analysis | 21 |
| Country | Russia |
|---|---|
| Market Share (2023) | 5.6% |
| Market Share (2033) | 5.7% |
| BPS Analysis | 1 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 5.4% |
| BPS Analysis | 25 |
| Country | Canada |
|---|---|
| Market Share (2023) | 4.1% |
| Market Share (2033) | 3.9% |
| BPS Analysis | -19 |
The USA will dominate the global market of glaucoma treatment in 2023 with a market share of 29.7% in global glaucoma treatment market. The rising prevalence of various types of glaucoma in the region would boost the demand for glaucoma therapies.
The market will grow as more people become aware of the importance of eye care and the associated diagnoses and treatments. The region's significant presence of important market companies involved in new drug research and product approvals would boost regional industry growth.
Due to the increased glaucoma incidence and improved healthcare infrastructure, the United States is likely to be the largest glaucoma treatment industry. According to the BrightFocus Foundation, more than 3 million Americans are affected by glaucoma, with open-angle glaucoma being the most frequent type.
Glaucoma costs the USA economy around USD 2.86 billion in direct costs and productivity losses each year. Many organizations in the United States are raising awareness of glaucoma, which is projected to boost the market's overall growth.
Germany will hold the market share of 5.2% for its glaucoma treatment in 2023 global market.
Glaucoma is one of the leading causes of blindness in the world. Around 500,000 people in Germany have high intraocular pressure, and 10% of them are at risk of going blind. The number of unreported cases, however, is likely to be even higher. Glaucoma affects both men and women at a younger age. Acute glaucoma can strike at any age, but the risk rises significantly with age. Women are more vulnerable than men.
According to hospital quality reports, glaucoma treatment in Germany became more efficient from classical to modern treatment procedures after 2006, and it became a potential for stringent repayment guidelines.
The Indian Glaucoma treatment sector is expected to grow at a CAGR of 4.3% between 2023 and 2033.
Market expansion is fuelled by the rising elderly population as well as innovations in glaucoma and cataract surgery equipment technology. The development of micro-invasive glaucoma drainage implants, which are used to treat glaucoma and offer a safer and less intrusive means of reducing intraocular pressure (IOP) as compared to standard glaucoma surgery devices, is another area where manufacturers are placing more emphasis.
However, a shortage of qualified experts, a refusal to pay for the use of glaucoma and cataract surgical tools, and the exorbitant cost of cataract operation, particularly in emerging economies hinder market expansion. The government and other charitable groups' efforts to educate the public about the advantages of cataract surgery, eye problems, and the availability of cutting-edge technology have also opened up lucrative market potential in India.
Open angle Glaucoma disease type will contribute market share for about 81.35% in 2023 global market and it is expected to be stable through the forecast.
The most common type of glaucoma in the population is primary open angle glaucoma (POAG). According to a glaucoma genetics article published in the human molecular genetics journal, more than 57.5 million people worldwide were affected by POAG in 2020, with a global prevalence of 2.2%. As a result, rising glaucoma disease burden is expected to provide lucrative market growth opportunities.
The development of biologics is one of the main open angle glaucoma therapeutics industry trends driving market expansion. Several biologics are being developed for the treatment of open angle glaucoma. These drugs are expected to be more effective and safer than small molecules. As a result, it is expected that the development of such new biologics for the treatment of open angle glaucoma will meet the unmet need for an innovative and secure treatment of open-angle glaucoma, assisting the market to expand to a certain amount over the forecast period.
The prostaglandin analogue sector will hold a 33.36% market share in the global market for treating glaucoma in 2023 because ophthalmic drugs are becoming more widely accessible and available. Prostaglandin analogues are widely used to lower intraocular pressure due to their effectiveness, once-daily dose, lack of adverse effects, and improved recovery rates in the treatment of glaucoma, which will drive market demand. It is also projected that rising demand for prostaglandin medications in combination therapy would present the market with significant potential prospects. The overall market statistics will be further boosted by growing consumer awareness of early glaucoma therapy and an increase in the number of patients receiving early eye illness diagnosis.
Hospital pharmacies segment will hold the market share of 56.55% in 2023 globally. The demand for hospital pharmacies will be boosted by the increased availability of innovative medications.
In 2022, the hospital pharmacy segment was worth more than USD 3 billion. Throughout the analysis, the segment is expected to grow significantly. The significant growth is due to the widespread availability of products in various settings for various forms of glaucoma therapy.
Patient's preference for hospital pharmacies for prescribed medications also contributes to income growth. Reimbursement rules and insurance coverage for drug purchases made in hospital settings are also expected to improve market predictions.
The key companies in the glaucoma treatment are concentrating their efforts on partnerships and collaborations as the primary means of increasing their geographical presence. These will aid market participants in expanding both their new product launch and market penetration.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the glaucoma treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania and Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Disease Type, Drug Class, Distribution Channel, and Region |
| Key Companies Profiled | AERIE Pharmaceuticals, Inc.; Cipla Inc.; Akorn Operating Company LLC; AbbVie; Bausch & Lomb Incorporated; Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market of glaucoma treatment is worth USD 5.7 Billion in 2022 and is set to expand 1.4X over the next ten years.
The global market in estimated to reach a valuation of USD 5.8 Billion in 2023.
Between 2017 and 2022, the global market expanded at the rate of 3.0%.
The market of glaucoma treatment is expected to reach USD 8.0 Billion by the end of 2033, with sales revenue expected to register 3.2% CAGR.
The global market is projected to expand at a CAGR of around 3.2% between 2023 and 2033.
The USA, China, Russia, Germany, and Canada are expected to drive demand for glaucoma treatment sector; and the market share of these top 5 countries will be 55.2% for the year 2022.
Europe is set to hold around 30.0% market share in the global market of glaucoma treatment in 2023.
AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. are the key players of glaucoma treatment market.
Open angle Glaucoma disease type presents market share for about 81.35% in 2023 global market.
North America is one of the key markets for glaucoma treatment sector, with the USA to account for about 29.7% of the global glaucoma treatment sector in the year 2023.
The market is valued at USD 5.8 billion in 2023.
A 3.2% CAGR is expected between 2023 and 2033 for the market.
In 2022, the top 5 countries held 55.2% of the market share.
The United States is estimated to generate a 29.8% share by 2033.
Open and glaucoma disease is to hold an 81.35% share in 2023.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Type 7.1. Open Angle Glaucoma 7.2. Angle Closure Glaucoma 7.3. Other 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Prostaglandin Analog 8.2. Beta Blockers 8.3. Adrenergic Agonist 8.4. Carbonic Anhydrase Inhibitors 8.5. Others 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. Middle East & Africa 11. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 17. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. AERIE Pharmaceuticals, Inc. 19.2. Cipla Inc. 19.3. Akorn Operating Company LLC 19.4. AbbVie 19.5. Bausch & Lomb Incorporated 19.6. Inoteck Pharmaceuticals 19.7. Merck & Co. Inc. 19.8. Novartis AG 19.9. Pfizer Inc. 19.10. Santen Pharmaceutical Co. Ltd. 19.11. Teva Pharmaceutical Industries Ltd. 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Glaucoma Treatment Market
